Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy in perioperative treatment of locally advanced head and neck squamous cell carcinoma
ChiCTR2000037980Phase 2Completed
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Two-year event-free survival rate. Started Dec 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2000037980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037980.